CIA
MDGL icon

Cape Investment Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cape Investment Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.83K Buy
+9
New +$4.61K ﹤0.01% 1037
2026
Q1 		– Sell
-9
Closed -$5.24K – 789
2025
Q4 		$5.24K Hold
9
– – ﹤0.01% 894
2025
Q3 		$4.13K Hold
9
– – ﹤0.01% 554
2025
Q2 		$2.72K Buy
+9
New +$2.68K ﹤0.01% 891

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cape Investment Advisory's MDGL Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 9 shares worth $4.83K. The stake represents ﹤0.01% of the portfolio and ranks #1037 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in MDGL as recently as Q4 2025.

Cape Investment Advisory first reported a position in MDGL in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.24K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Cape Investment Advisory held 9 shares of Madrigal Pharmaceuticals worth $4.83K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1037 holding.
  • Cape Investment Advisory first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Cape Investment Advisory's Madrigal Pharmaceuticals position peaked at $5.24K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.